Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026
Rhea-AI Summary
Anixa Biosciences (NASDAQ: ANIX) announced Dr. Amit Kumar, chairman and CEO, will present at the Water Tower Research Insights Conference on April 14, 2026 at 12:30 pm ET. The virtual presentation will cover company strategy, clinical programs, and recent trial highlights.
Key clinical updates noted include a breast cancer vaccine that met primary endpoints with protocol-defined immune responses in 74% of participants in a Phase 1 trial, and ongoing Phase 1 ovarian CAR-T therapy lira-cel reporting positive survival data.
Positive
- None.
Negative
- None.
News Market Reaction – ANIX
In the Apr 7 session, ANIX gained 3.86%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | Media interview | Positive | +1.6% | CEO discussed advancing immunotherapy pipeline and positive Phase 1 data. |
| Apr 01 | Clinical update | Positive | +5.4% | Reported final positive Phase 1 vaccine results and Phase 2 manufacturing plans. |
| Mar 30 | Conference presentation | Positive | -2.0% | Announced upcoming presentation on ovarian CAR‑T Phase 1 trial design and status. |
| Mar 12 | Podcast feature | Positive | -2.7% | CEO featured on podcast discussing positive trial data and company outlook. |
| Mar 09 | IP expansion | Positive | +4.6% | Received Korean patent allowance covering breast cancer vaccine technology. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinically focused and investor-outreach news has produced mixed reactions, with both aligned gains and occasional selloffs on otherwise positive updates.
Over the past month, ANIX has repeatedly highlighted progress in its breast cancer vaccine and ovarian cancer CAR‑T programs. Positive Phase 1 breast cancer vaccine data, including protocol‑defined immune responses in 74% of participants, and encouraging survival data from the lira‑cel CAR‑T trial have been shared via clinical updates, conferences, and media appearances. Some of these events (e.g., Apr 1 and Mar 9) coincided with notable price gains, while others (such as the Mar 12 podcast) saw negative reactions, underscoring inconsistent trading responses to similar themes.
Key Terms
car-t therapy medical
phase 1 clinical trial medical
phase 1 clincial trial medical
protocol-defined immune responses medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in
Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1 clincial trial
The presentation will be hosted by WTR Analyst, Robert Sassoon, Managing Director at Water Tower Research, and will cover several topics, including:
- Overview of the Company and its business model
- Breast cancer vaccine met primary endpoints and generated protocol-defined immune responses in
74% of participants in Phase 1 clinical trial - Ovarian cancer CAR-T therapy, lira-cel, exhibiting positive survival data in ongoing Phase 1 clinical trial
The WTR Insights Conference is a virtual event designed for investors seeking direct access to company management teams and differentiated insights across innovative businesses spanning all sectors covered by Water Tower Research. Through a series of fireside chat discussions and curated post-event engagement opportunities, attendees will gain a deeper understanding of each company's strategy, competitive positioning, and long-term growth outlook.
Advance registration is encouraged to secure access to the full agenda, company lineup, and live sessions, as well as on-demand replays following the event. Registration may be completed at: Event Registration.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of liraltagene autoleucel, or lira-cel, an ovarian cancer immunotherapy being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-to-participate-in-water-tower-research-insights-conference-on-april-14-2026-302735183.html
SOURCE Anixa Biosciences, Inc.